Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial
Georgios J. Vlachojannis1, MD, PhD; Pieter C. Smits1*, MD, PhD; Sjoerd H. Hofma2, MD, PhD; Mario Togni3, MD; Nicolás Vázquez4, MD; Mariano Valdés5, MD; Vassilis Voudris6, MD; Serban Puricel3, MD; Ton Slagboom7, MD; Jean-Jacques Goy3, MD; Peter den Heijer8, MD, PhD; Martin van der Ent1, MD, PhD
1. Department of Cardiology, Maasstad Hospital, Rotterdam, The Netherlands; 2. Department of Cardiology, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands; 3. Department of Cardiology, Hôpital Cantonal de Fribourg, Fribourg, Switzerland; 4. Departme
Aims: The aim of this analysis was to compare the long-term safety and efficacy of the biodegradable polymer biolimus-eluting stent (BES) with that of the durable polymer everolimus-eluti
